At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Wolfgang Hiddemann, MD, PhD, from the University of Munich, Munich, Germany, provides an overview of chemotherapy-free approaches in clinical development for the treatment of patients with indolent lymphoma. Promising approaches include the Bruton tyrosine kinase inhibitor, ibrutinib, and PI3K-delta inhibitor, idelalisib, in combinations with anti-CD20 monoclonal antibodies; Bcl-2 inhibitors; and PD-1 immune checkpoint inhibitors.
Institution website: http://www.klinikum.uni-muenchen.de/Medizinische-Klinik-und-Poliklinik-III/de/team/hiddemann_w/index.html
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates